0.40Open0.05Pre Close25 Volume328 Open Interest10.00Strike Price1.00KTurnover110.72%IV11.11%PremiumMay 16, 2025Expiry Date0.00Intrinsic Value100Multiplier5DDays to Expiry0.40Extrinsic Value100Contract SizeAmericanOptions Type0.3317Delta0.2961Gamma37.44Leverage Ratio-0.0456Theta0.0004Rho12.42Eff Leverage0.0040Vega
Stoke Therapeutics Stock Discussion
Stoke Therapeutics Taps Former Vertex COO as Interim CEO Amid Breakthrough Drug Progress
Stoke Therapeutics Receives FDA Breakthrough Therapy Designation for Zorevunersen for the Treatment of Dravet Syndrome
No comment yet